Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies
Jakob Kristinsson,1 Jón Snaedal,2 Gudlaug Tórsdóttir,1,2 Torkell Jóhannesson11Department of Pharmacology and Toxicology, University of Iceland, Reykjavik, Iceland; 2Department of Geriatrics, Landspitali University Hospital, Reykjavik, Icela...
Guardado en:
Autores principales: | Kristinsson J, Snaedal J, Tórsdóttir G, Jóhannesson T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dd13995211df446cbde251f2cf38d684 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Did depressive symptoms affect recognition of emotional prosody in Parkinson’s disease?
por: Adriana Vélez Feijó, et al.
Publicado: (2008) -
A review of the potential therapeutic role of statins in the treatment of Alzheimer’s disease: current research and opinion
por: Mitchell AJ, et al.
Publicado: (2013) -
An update on the toxicity of Aβ in Alzheimer’s disease
por: Jürgen Götz, et al.
Publicado: (2008) -
Parkinson’s disease patients’ subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life
por: Skogar Ö, et al.
Publicado: (2012) -
Psychiatric disorders in primary focal dystonia and in Parkinson’s disease
por: Fernando MV Dias, et al.
Publicado: (2011)